Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 393-400

  Kolesar, Jill ^a,b   Brundage, Richard C ^c   Pomplun, Marcia ^a   Alberti, Dona ^a,d   Holen, Kyle ^a,d   Traynor, Anne ^a,d   Ivy, Percy ^e   Wilding, George ^a,d  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

3 aminopyridine 2 carboxaldehyde thiosemicarbazone; Phase 1; Population pharmacokinetics; Triapine

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; DOXORUBICIN; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE; ABCB1 PROTEIN, HUMAN; GLYCOPROTEIN P; PYRIDINE DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; ERYTHROCYTE; FEMALE; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOXIA; MALE; MOLECULAR MODEL; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEX DIFFERENCE; BIOLOGICAL MODEL; BLOOD; BODY SURFACE; COMPUTER SIMULATION; GENETICS; GENOTYPE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); SEXUAL DEVELOPMENT; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD; BODY SURFACE AREA; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; ERYTHROCYTES; FEMALE; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASMS; P-GLYCOPROTEIN; PYRIDINES; SEX CHARACTERISTICS; THIOSEMICARBAZONES;

EID: 79953793175     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1331-z     Document Type: Article

References (23)

1. Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC (1999) Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 39:3-12
2. Cory JG, Cory AH, Rappa G, Lorico A, Liu MC, Lin TS, Sartorelli AC (1994) Inhibitors of ribonucleotide reductase. Comparative effects of amino-and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem Pharmacol 48:335-344
3. Schelman WR, Holen K, Mulkerin D, Kolesar J, Thomas J, Kruse M, Oliver K, Marnocha R, Eickhoff J, Wilding G (2006) J Clin Oncol ASCO Annu Meet Proc Part I 24 (18S) (June 20 Supplement): 12011
4. Chang JE, Morgan Meadows S, Traynor A, Kolesar J, Marnocha R, Lee F, Eickoff J, Beth E, Binger K, Wilding G (2006) J Clin Oncol ASCO Annu Meet Proc Part I 24 (18S) (June 20 Supplement): 13168
5. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD (2008) A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 26(4):369-379
6. Mackenzie MJ, Saltman D, Hirte H, Low J, Johnson C, Pond G, Moore MJ (2007) A phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium. Invest New Drugs 25(6):553-558
7. Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA (2007) Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs 25(5):471-477 (Pubitemid 47222906)
8. Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, Thein M, Sznol M, Low J (2008) A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk Res 32(1):71-77 (Pubitemid 350100849)
9. Gojo I, Tidwell ML, Greer J, Takebe N, Seiter K, Pochron MF, Johnson B, Sznol M, Karp JE (2007) Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res 31(9):1165-1173
10. Dalal BI, Kollmannsberger C (2005) Drug-induced haemolysis and methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency. Br J Haematol 129(3):291 (Pubitemid 40646886)
11. Foltz LM, Dalal BI, Wadsworth LD, Broady R, Chi K, Eisenhauer E, Kobayashi K, Kollmannsburger C (2006) Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. Am J Hematol 81(3):210-211
12. Ma B, Goh BC, Tan EH, Lam KC, Soo R, Leong SS, Wang LZ, Mo F, Chan AT, Zee B, Mok T (2008) A multicenter phase II trial of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs 26(2):169-173 (Pubitemid 351357710)
13. Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7):3473-3478 (Pubitemid 30183327)
14. Rappa G, Lorico A, Liu M-C, Kruh GD, Cory AH, Cory JG, Sartorelli AC (1997) Overexpression of the multidrug resistance genes mdr1, mdr3 and mrp in L1210 leukemia cells reisitant to inhibitors of ribonucleotide reductase. Biochem Pharmacol 54:649-655 (Pubitemid 27404624)
15. Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM (2009) A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol 63(6):1147-1156
16. Schelman WR, Holen K, Mulkerin D et al. (2006) A phase I study of triapine in combination with irinotecan in refractory tumors. J Clin Oncol ASCO Ann Meet Proc Part I 24 (18S) (June 20 Supplement): 12011
17. Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M (2003) Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 9(11):4092-4100 (Pubitemid 37204025)
18. Kolesar JM, Hamidovic A, Hahn K (2009, Apr. 28) Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract
19. Traynor AM, Lee JW, Bayer GK, Tate JM, Thomas SP, Mazurczak M, Graham DL, Kolesar JM, Schiller JH (2009, Feb. 24) A phase II trial of Triapine (R) (NSC 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs [Epub ahead of print]
20. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD (2008, Aug) A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 26(4):369-379 [Epub 2008 Feb. 16]
21. Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE (2008) Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. J Inorg Biochem 102(4):693-698 (Pubitemid 351375031)
22. Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794(5):860-871
23. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A (2007) Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 12(8):913-923 (Pubitemid 47359133)